Newron Pharmaceuticals — Moving full steam towards pivotal studies

Newron Pharmaceuticals (SIX: NWRN)

Last close As at 10/10/2024

CHF7.35

−0.20 (−2.65%)

Market capitalisation

CHF144m

More on this equity

Research: Healthcare

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Newron Pharmaceuticals’ H124 results reflect a period of positive traction for lead clinical asset evenamide, with stellar clinical data as an add-on treatment in schizophrenia, building a strong foundation for the upcoming, potentially pivotal Phase III programme (study 017). While the Phase III trial will initially focus on treatment-resistant schizophrenia (TRS), we note the likelihood of the trial expanding to cover patients with poorly managed symptoms, as evaluated in the prior Phase II/III 008A study, which we have reflected in our estimates. With discussions focused on securing the most beneficial partnering option, management expects the trial to initiate in H125, with funding in place to achieve this milestone. Our valuation adjusts to CHF245.8m or CHF12.8/share (previously CHF219.1m or CHF12.3/share).

Written by

Arron Aatkar

Analyst

Healthcare

Newron Pharmaceuticals

Moving full steam towards pivotal studies

H124 results

Pharma and biotech

23 September 2024

Price

CHF7.71

Market cap

CHF149m

€1.06/CHF

Net debt (€m) at end-June 2024

36.3

Shares in issue (including 200k shares issued in September 2024)

19.3m

Free float

95%

Code

NWRN

Primary exchange

SIX Swiss Exchange

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

5.9

(22.8)

55.0

Rel (local)

8.9

(21.5)

44.9

52-week high/low

CHF11.0

CHF4.2

Business description

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease is sold in Europe, Japan and the United States. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Next events

Evenamide partner finalisation

Q424

Evenamide study 017 initiation

H125

Analysts

Dr Arron Aatkar

+44 (0)20 3077 5700

Jyoti Prakash, CFA

+44 (0)20 3077 5700

Newron Pharmaceuticals is a research client of Edison Investment Research Limited

Newron Pharmaceuticals’ H124 results reflect a period of positive traction for lead clinical asset evenamide, with stellar clinical data as an add-on treatment in schizophrenia, building a strong foundation for the upcoming, potentially pivotal Phase III programme (study 017). While the Phase III trial will initially focus on treatment-resistant schizophrenia (TRS), we note the likelihood of the trial expanding to cover patients with poorly managed symptoms, as evaluated in the prior Phase II/III 008A study, which we have reflected in our estimates. With discussions focused on securing the most beneficial partnering option, management expects the trial to initiate in H125, with funding in place to achieve this milestone. Our valuation adjusts to CHF245.8m or CHF12.8/share (previously CHF219.1m or CHF12.3/share).

Year end

Revenue
(€m)

PBT*
(€m)

EPS*
(€)

DPS
(€)

P/E
(x)

Yield
(%)

12/22

6.09

(17.0)

(0.95)

0.0

N/A

N/A

12/23

9.06

(16.0)

(0.90)

0.0

N/A

N/A

12/24e

24.30

1.5

0.06

0.0

136.2

N/A

12/25e

7.33

(8.3)

(0.43)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Strong clinical data in H124 support pivotal studies

H124 saw multiple key milestones for Newron’s development efforts, with the company reporting two sets of encouraging clinical results from separate studies for evenamide. The top-line one-year results from study 014/015 (TRS patients; n=161) met all endpoints with statistical significance. Notably, c 25% of patients were reported to have achieved clinical remission, a first for this sub-population, to our knowledge. These findings were complemented by the results of study 008A (poorly managed schizophrenia; n=291), which met its primary endpoint and key secondary endpoints. We believe that with its robust data package, evenamide is well-positioned ahead of the potentially registrational programme.

All eyes now on securing partnership for evenamide

Initiation of study 017 rests on Newron securing a partnership deal, and management has highlighted that all possible options (a regional or global licensing deal, or an M&A transaction) remain on the table. With several indications of interest received by the company, the transaction is expected to be closed in the coming months, ahead of an H125 study launch. It will be a potentially pivotal, randomised, double-blind, one-year, placebo-controlled trial (estimated n=≥400) to assess the efficacy, safety and tolerability of evenamide as an adjuvant in TRS patients. Despite the slight shift in trial initiation timelines (from late-2024 to H125), we continue to estimate a 2027 launch, raising the probability of approval to 70% (60% previously).

Valuation: CHF245.8m or CHF12.8 per share

We tweak our estimates to reflect FX changes, the latest net cash figure, H124 performance and visibility of trial plans and timelines. We now expect the poorly responding patient cohort (c 40% of all schizophrenia patients) to be studied as an add-on indication for label expansion. Our valuation adjusts to CHF245.8m or CHF12.8/share (previously CHF219.1m or CHF12.3/share).

Building evenamide’s resume in schizophrenia

Newron is a biopharmaceutical company focused on the development of innovative treatments for conditions of the central nervous system (see Exhibit 1).

Exhibit 1: Newron’s product pipeline

Source: Newron half-year report 2024. Note: We understand that the ralfinamide programme is currently on hold, while the company is focused on the clinical development of evenamide as a top strategic priority.

Xadago

The company’s first marketed product is Xadago (safinamide), which is used as an add-on therapy for patients with Parkinson’s disease (PD). With support from partners Zambon, Supernus and Meiji Seika, the drug has generated steady royalty income for Newron (€3.4m in H124 versus €3.2m in H123), although with approaching maturity (market exclusivity in place until at least 1 December 2027) the strategic focus is now on advancing evenamide, a drug that holds blockbuster potential, based on highly encouraging data from prior clinical trials.

Evenamide

Evenamide is currently in the late stages of clinical development for poorly managed schizophrenia and TRS. It has a unique mechanism of action as a voltage-gated sodium channel inhibitor and modulator of post-synaptic glutamate release, which aims to move beyond the traditional dopamine hypothesis of schizophrenia pathophysiology. The mechanism appears to be effective, reflected in the positive clinical data reported to date. In January 2024, the company reported final results from the Phase II study 015 (extension of study 014) in TRS, which demonstrated statistically significant improvements across all standard efficacy measures including Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S) Scale and Level of Functioning (LOF) measures versus baseline. Over 70% of patients experienced a clinically meaningful reduction in schizophrenia severity and c 50% of patients no longer met the protocol severity criteria for a diagnosis of treatment-resistance at the 12-month timepoint. 25% of patients were described as achieving remission, which has not been observed previously in TRS patients to our knowledge, raising the expectation for an efficacious treatment strategy for this sub-population. The drug also showed desirable safety and tolerability. The sentiment towards evenamide improved further with the release of the results from the Phase II/III study (008A) in April/May 2024, focused on poorly managed schizophrenia, which also met its primary endpoint of improvement on the PANSS score from baseline, and the key secondary endpoint of improvement on the CGI-S scale. Notably, 31.3% of patients receiving evenamide were rated ‘much improved’, versus 17.3% on placebo, consolidating the already robust data from study 014/015, albeit in a larger, randomised, placebo-controlled setting.

The next focus area for Newron will be to reproduce these observations in the upcoming, potentially pivotal Phase III programme (study 017), which management expects to commence in H125. We note that while this is a slight delay from the previously communicated late-2024 expectations, it is not entirely unexpected given that partnering discussions can be a protracted business as the company seeks to maximise the potential commercial terms with prospective partners. Study 017 will be a randomised, double-blind, multinational, potentially pivotal trial, designed to compare evenamide to placebo as an add-on treatment in at least 400 TRS patients. The primary endpoint will be the change from baseline in PANSS scores at week 12. This will be followed by a continuation to week 26 and to one year to evaluate long-term safety. The reported data to date provide a strong foundation in addressing schizophrenia, in our view, and we believe the announcement of a transaction in the coming months will be Newron’s next significant catalyst.

Schizophrenia afflicts c 1% of the global population and despite the availability of several treatment options, one-third of the population remains treatment resistant and a further 40% respond poorly to prescribed medication. While the second-generation antipsychotic clozapine has been approved for TRS, it is prescribed to only around 5% of patients, in part due to a strong side-effect profile. Evenamide has proven to be safe in completed clinical studies, with study 008A data reporting safety and tolerability similar to placebo (25.0% for evenamide vs 25.8% for placebo).

As discussed above, while study 017 will focus on TRS, we see a high probability of the company seeking to expand the trial design (or undertake another new trial) to assess the drug’s utility in patients responding poorly to existing schizophrenia treatments. Together with TRS, this cohort covers c 70% of the total affected schizophrenia population, a material commercial opportunity for Newron.

Financials

Given that lead asset evenamide is still undergoing clinical development, Newron’s primary source of revenues has been the royalty income stream from its marketed product, Xadago (safinamide), targeting PD. In H124, the company reported royalty income of €3.4m, up 6.1% y-o-y, and we believe this to be attributed entirely to Xadago. However, no other income related to customer contracts was recorded in the period (€2.3m in H123), resulting in overall revenue declining by c 38%. Total operating expenses increased by 13.2% y-o-y to €11.1m in H124, with R&D expenses contributing c 58% (€6.5m; €5.7m in H123). The increase in R&D expenses was attributed to the clinical work on evenamide, particularly the Phase II/III study 008A, with reported top-line results in April/May 2024. With clinical activity complete and the Phase III study 017 now expected to commence in H125, we anticipate H224 R&D expenses to be materially lower. SG&A expenses in H124 were €4.6m, compared to €4.1m in H123, due to higher costs related to consultancy and other professional services. Overall, the company reported an operating loss of €7.7m, 78.4% higher than the €4.3m in operating losses recognised in H123. The net loss for the period was €9.6m (€7.0m in H123) and included €2.2m in interest expenses related to the €40m European Investment Bank (EIB) loan. Following the renegotiation with the EIB in March 2024 on loan terms and maturity (discussed below), we expect interest expenses to rise in H224. Reflecting the operating performance, cash outflow from operations increased to €8.8m, from €5.6m in H123.

Based on the H124 results and further visibility on the company’s clinical trial plans, we have made certain adjustments to our estimates. We continue to estimate the company signing a licensing agreement in Q424 for an upfront payment of €25m, which we have included on a risk-adjusted basis as licensing revenue in FY24. We note that this figure is subject to modification based on the actual terms of the deal to be signed by Newron. We also estimate €6.8m in royalty income for Xadago during the year, resulting in an overall revenue estimate of €24.3m, similar to our last published figure. For FY25, we now remove the licensing income we had previously assumed, given the slight pushback in trial timelines. Our revised revenue estimate for FY25 is €7.3m, versus €27.1m previously. We also trim our R&D expense estimates for FY24 to €10.4m (from €14.4m previously) due to the reasons stated above (delay in initiation of Phase III clinical trial). For FY25, we reflect a major decline in R&D (€3.6m vs €15.6m previously) on the expectation that the partner will take over all development work for evenamide, from Phase III clinical trials onwards. On the other hand, we increase our SG&A estimate for FY24 slightly to €8.1m, from €7.9m previously, to reflect the H124 run rate. The corresponding figure for FY25 stays unchanged at €8.3m. Overall we now project an operating income of €5.8m in FY24 (€2.0m previously) and an operating loss of €4.5m in FY25 (operating profit of €3.2m previously).

At end-H124, Newron had a gross cash position of €7.9m, plus €4.3m in other current financial and liquid assets. The cash balance was supported by capital inflow from the private placement of up to 2.05m shares (for proceeds of up to €15m at €7.3/share, a 5% discount to the last trading price of €7.7) to an institutional investor in March 2024 (to be exercised by 31 January 2025). We calculate the investor to have subscribed to 1.15m shares by end-June 2024, for proceeds of c €8.4m. We also understand that a further 200,000 shares have been subscribed to post-period for an estimated €1.5m. In total, options to subscribe for 1.35m of the 2.05m shares have been exercised by the investor to date, for total proceeds of €9.9m. The company also has €48.5m of debt on its books, comprising the €40m loan from the EIB as well as accrued interest. As highlighted in our previous update note, Newron successfully renegotiated its terms with the EIB in March 2024, resulting in deal maturity for the first three (of the total five) traches to be pushed out to late 2025/26. The first €10m tranche will now be due in November 2025 (versus June 2024 previously) with the other four tranches maturing in 2026. Based on our cash burn projections, we expect the current gross cash position to provide a runway for the company through H125, consistent with management guidance and past the planned initiation of the Phase III trial. If we were to include the assumed €17.5m in risk-adjusted upfront payment from the evenamide partnership deal (which we reflect in our model), the cash runway would extend further.

Valuation

We value Newron using a risk-adjusted net present value (rNPV) approach for its two programmes. For the marketed asset Xadago, we project cash flows to the end of market exclusivity in 2029 in Europe and December 2027 in the US (which accounts for c 10% of the global royalty income for the drug), assuming a steady decline thereafter. We also assume a discount rate of 10%, which is the Edison standard rate for commercial-stage biopharma assets. Evenamide, which we had previously segregated under two separate target indications (TRS and poorly responding patients), is now combined under one programme. This is based on our assumption that the company may explore the drug as a label expansion opportunity in the poorly responding cohort, following the TRS trial. Given the encouraging clinical data to date and the significant unmet need, we estimate peak sales potential of €1.1bn, adding evenamide to the coveted list of blockbuster drugs, if successful. We also increase the probability of success to 70%, from 60% previously, and continue to estimate a launch timeline of 2027 (notwithstanding the slight delay in trial initiation, as indicated previously). For evenamide, we use a discount rate of 12.5% given the higher risk associated with a clinical-stage asset.

Based on the aforementioned modifications and adjustments related to forex changes and capital position, our overall valuation for Newron improves to CHF245.8m, versus CHF219.1m previously (Exhibit 2). The per share value rises as well to CHF12.8 (from CHF12.3), although the upgrade was truncated due to the higher number of shares outstanding (19.26m vs 17.85m in our last update).

Exhibit 2: Newron valuation breakdown

Product

Indication

Launch

Probability

rNPV
(CHFm)

NPV/share (CHF/share)

Xadago

Parkinson’s disease

2015

100%

28.4

1.5

Evenamide

Schizophrenia – TRS/non-responders

2027

70%

289.0

15.0

Total direct product value

 

 

 

317.4

16.5

 

Direct costs to 2033 less tax

(38.9)

(2.0)

Pro-forma gross cash at end-June 2024

12.9

0.7

Loans (fair value June 2024)

(45.6)

(2.4)

Valuation

 

 

 

245.8

12.8

Source: Edison Investment Research. Note: Per share valuation based on 19,258,859 shares outstanding.

Our valuation assumes that Newron will sign a global licensing deal for evenamide in Q424 with a total deal value of €650m (including development and commercial milestone payments) and an upfront payment of €25m. We also assume a tiered royalty rate of 12–15% based on certain sales targets. Any change to these will entail an adjustment to our valuation.

As an added sensitivity, if we were to assume no partnership deal for evenamide and Newron undertaking the Phase III clinical studies on its own (assuming a trial cost of €45m), we estimate that the company would need to raise c €80m in funds (excluding the potential c €5m still available under subscription from the institutional investor) across FY25–27 before the expected market launch later in 2027. If these funds are raised through an equity issue, Newron would have to issue 10.4m shares (at the last trading price of CHF7.71/share), resulting in our per share valuation diluting to CHF10.8 from CHF12.8 currently (shares outstanding would increase from 19.3m to 29.6m). We note that the estimated €80m in capital requirement includes the funds deployed in repayment of the €40m EIB loan between FY25 and FY26. If Newron were to be successful in renegotiating its repayment terms with EIB again, the requirement for external capital would reduce proportionately.

Exhibit 3: Financial summary

Accounts: IFRS; year end 31 December; €000s

 

2021

2022

2023

2024e

2025e

PROFIT & LOSS

 

 

 

 

 

 

Total revenues

 

5,762

6,094

9,057

24,298

7,334

Cost of sales

 

0

0

0

0

0

Gross profit

 

5,762

6,094

9,057

24,298

7,334

Total operating expenses

 

(18,119)

(19,396)

(20,686)

(18,538)

(11,878)

Research and development expenses

 

(10,725)

(12,005)

(13,152)

(10,444)

(3,577)

SG&A

 

(7,394)

(7,391)

(7,534)

(8,095)

(8,301)

EBITDA (normalized)

 

(11,386)

(12,620)

(11,231)

6,215

(4,422)

Operating income (reported)

 

(12,357)

(13,302)

(11,629)

5,760

(4,544)

Finance income/(expense)

 

(2,527)

(4,170)

(4,571)

(4,578)

(3,735)

Exceptionals and adjustments

 

0

0

0

0

0

Profit before tax (reported)

 

(14,884)

(17,472)

(16,200)

1,182

(8,279)

Profit before tax (normalised)

 

(14,122)

(16,992)

(16,003)

1,482

(8,279)

Income tax expense (includes exceptionals)

 

(17)

(21)

(24)

(284)

0

Net income (reported)

 

(14,901)

(17,493)

(16,224)

898

(8,279)

Net income (normalised)

 

(14,139)

(17,013)

(16,027)

1,198

(8,279)

Basic average number of shares, m

 

17,845.0

17,845.0

17,845.0

18,857.5

19,226.9

Basic EPS (€)

 

(0.84)

(0.98)

(0.91)

0.05

(0.43)

Adjusted EPS (€)

 

(0.79)

(0.95)

(0.90)

0.06

(0.43)

 

 

 

 

 

 

 

BALANCE SHEET

 

 

 

 

 

 

Property, Plant and Equipment

 

87

72

53

39

29

Right of use assets (leases)

 

490

455

352

280

223

Intangible Assets

 

2

0

0

0

0

Non-current receivables (Tax credits)

 

10,480

8,175

5,809

1,732

336

Total non-current assets

 

11,059

8,702

6,214

2,051

588

Cash and equivalents

 

25,019

13,424

6,338

25,781

7,780

Current financial assets

 

9,575

9,350

6,261

4,245

4,245

Inventories

 

0

0

0

0

0

Trade Accounts Receivable

 

4,833

5,719

7,053

6,386

6,720

Total current assets

 

39,427

28,493

19,652

36,412

18,744

Trade Accounts Payable

 

3,504

4,869

6,106

7,683

6,894

Other Current Liabilities

 

150

172

543

543

543

Short-term Debt

 

0

0

22,277

0

30,000

Total current liabilities

 

3,654

5,041

28,926

8,226

37,437

Long-term Debt

 

42,542

45,165

25,753

48,030

8,030

Leasing Obligations

 

389

325

210

133

69

Share based liabilities

 

213

220

473

473

473

Long-term Provisions

 

581

474

412

412

412

Total non-current liabilities

 

43,725

46,184

26,848

49,048

8,984

Equity attributable to company

 

3,107

(14,030)

(29,908)

(18,810)

(27,089)

 

 

 

 

 

 

 

CASH FLOW STATEMENT

 

 

 

 

 

 

Pre-tax profit

 

(14,884)

(17,472)

(16,200)

1,182

(8,279)

Net Financial Income

 

(792)

(1,183)

(1,162)

10

6

Tax

 

0

0

0

(284)

0

Depreciation and amortisation

 

209

202

201

155

122

Share based payments

 

762

480

197

300

0

Other adjustments

 

3,524

4,996

5,311

4,077

1,396

Movements in working capital

 

(264)

1,885

1,513

2,244

(1,122)

Cash from operations (CFO)

 

(11,445)

(11,092)

(10,140)

7,684

(7,876)

Capex

 

(20)

(18)

(11)

(69)

(55)

Acquisitions & disposals net

 

0

0

0

0

0

Other investing activities

 

8,440

(299)

3,257

2,016

0

Cash used in investing activities (CFIA)

 

8,420

(317)

3,246

1,947

(55)

Loans received

 

15,000

0

0

0

0

Loan repayments

 

0

0

0

0

(10,000)

Equity issued

 

0

0

0

9,900

0

Other Financing Cash Flows (leases)

 

(169)

(186)

(192)

(88)

(70)

Cash from financing activities (CFF)

 

14,831

(186)

(192)

9,812

(10,070)

Cash and equivalents at beginning of period

 

13,213

25,019

13,424

6,338

25,781

Increase/(decrease) in cash and equivalents

 

11,806

(11,595)

(7,086)

19,443

(18,001)

Effect of FX on cash and equivalents

 

0

0

0

0

0

Cash and equivalents at end of period

 

25,019

13,424

6,338

25,781

7,780

Net (debt)/cash (including liquid resources)

 

(7,948)

(22,391)

(35,431)

(18,004)

(26,005)

Source: Company documents, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by Newron Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Newron Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by Newron Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Newron Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Newron Pharmaceuticals

View All

Latest from the Healthcare sector

View All Healthcare content

Research: TMT

IP Group — Management sees positive portfolio momentum

IP Group reported broadly stable private portfolio values in H124, assisted by the positive revaluation of Featurespace, an AI-powered fraud and financial crime detection business, which delivered strong top-line growth of 46.5% in 2023 to £50.4m. This helped offset a further carrying value reduction of First Light Fusion and a partial write-down of Ultraleap Holdings, a human-machine interface business. The de-rating of listed Oxford Nanopore (ONT) was therefore the major driver behind IP Group’s 9% NAV fall in total return (TR) terms in H124. Roughly half of ONT’s share price decline has reversed post reporting date, supported by its half-year trading update and the Novo Holdings investment. Across other life sciences holdings, there were four positive clinical trial results and only one failure. Importantly, IP Group has seen an uptick in exits in the year to date, with cash proceeds of £44.6m (c 4% of opening portfolio value, with £30m from the sale of Garrison Technology). This encouraged the company to increase the current buyback programme by £10m to £30m.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free